latest update:
[TrialBase DB]

trial summary · NCT07644650

Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors

A Phase 1, Multiregional, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MST-168, in Participants With Advanced Solid Malignant Tumors

Trial record from the TrialBase DB dataset, status RECRUITING, condition Neoplams, sponsored by Mabsoft Therapeutics (Shanghai) Co., Ltd.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07644650phase PHASE1enrollment 420start 2026-10-26

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.

Source record: https://clinicaltrials.gov/study/NCT07644650

Facts

registry idNCT07644650
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionNeoplams
sponsorMabsoft Therapeutics (Shanghai) Co., Ltd.
sponsor classINDUSTRY
enrollment420
start date2026-10-26
primary completion2028-06-30
completion2030-06-30
results postednot reported

Conditions

  • Neoplams

Interventions

  • MST-168

Countries

  • China

Intervention types: BIOLOGICAL

Work with this record